Filtered By:
Source: Journal of Stroke and Cerebrovascular Diseases
Drug: Plavix

This page shows you your search results in order of date.

Order by Relevance | Date

Total 43 results found since Jan 2013.

An elderly case with late carotid stent thrombosis: possible role of antiphospholipid antibodies
The case study speculates that the antiphospholipid antibodies acquired during the follow-up period of carotid artery stenting may cause late stent thrombosis that is resistant to direct oral anticoagulants. A 73-year-old man was hospitalized with complaints of weakness in the right lower extremity. The patient had undergone carotid artery stenting for symptomatic stenosis of the left internal carotid artery 6 years prior and had received antiplatelet therapy with clopidogrel 75  mg/day. As the patient had developed atrial fibrillation without stent stenosis at the age of 70 years, anticoagulation therapy with rivaroxaban...
Source: Journal of Stroke and Cerebrovascular Diseases - May 26, 2023 Category: Neurology Authors: Shinji Kitsuki, Kenji Fukuda, Tomonaga Matsushita, Yoshihisa Fukushima, Tetsuro Ago, Takanari Kitazono Tags: Case Report Source Type: research

Relationship between CYP2C19*2, *3 gene polymorphism and the recurrence in ischemic stroke patients treated with clopidogrel in China: A meta-analysis
The relationship between CYP2C19 *2,*3 gene variants and the recurrence in ischemic stroke patients treated with clopidogrel is still controversial according to the available published literature. To evaluate correlations between  CYP2C19 *2,*3 gene variants, metabolic typing according to *2, *3 SNPs (the polymorphism of rs4244285, rs4986893) and stroke recurrence, we performed this study through meta-analysis.
Source: Journal of Stroke and Cerebrovascular Diseases - October 7, 2022 Category: Neurology Authors: Yu Yan, Ruixiao Hao, Xiuyuan Zhao, Xiaoshuang Xia, Lin Wang, Xin Li Source Type: research

P2Y12 reaction units and ischemic and bleeding events after neuro-endovascular treatment
To investigate the associations of perioperative P2Y12 reaction units (PRU) measured using VerifyNow with ischemic and bleeding events, and to determine the PRU threshold in the setting of elective neuro-endovascular treatment (EVT) for intracranial/extracranial vascular disease in patients taking aspirin and clopidogrel.
Source: Journal of Stroke and Cerebrovascular Diseases - July 15, 2022 Category: Neurology Authors: Kyohei Fujita, Shoko Fujii, Sakyo Hirai, Hiroto Yamaoka, Mariko Ishikawa, Jun Karakama, Kazunori Miki, Masataka Yoshimura, Shigeru Nemoto, Kazutaka Sumita Source Type: research

Under Treatment of High-Risk TIA Patients with Clopidogrel-Aspirin in the Emergency Setting
Treating high-risk transient ischemic attack (TIA) with dual antiplatelet therapy (DAPT) reduces subsequent ischemic stroke risk yet current rates of clopidogrel-aspirin treatment are uncertain.
Source: Journal of Stroke and Cerebrovascular Diseases - October 11, 2021 Category: Neurology Authors: Andrea R. Lendaris, Samantha Lessen, Natalie T. Cheng, Benjamin W. Friedman, Charles Esenwa, Daniel L. Labovitz, Shyam Prabhakaran, Richard B. Lipton, Ava L. Liberman Source Type: research

Platelet Function Monitoring Performed after Carotid Stenting during Endovascular Stroke Treatment Predicts Outcome
Antiplatelets agents are widely used and effective for secondary prevention of vascular diseases. Some patients might have reduced platelet inhibition on antiplatelet therapy with a higher risk of ischemic complications.1,2 The role of platelet function monitoring (PFM) has been extensively investigated in cardiology. Resistance to Clopidogrel correlates with higher risk of long-term cardiovascular events and coronary stent thrombosis.3,4 Similarly, studies performed after elective carotid stenting showed that ischemic recurrence and early stent thrombosis are more common in non-responders to Clopidogrel.
Source: Journal of Stroke and Cerebrovascular Diseases - May 5, 2021 Category: Neurology Authors: Ludovico Ciolli, Nicoletta Lelli, Francesca Rosafio, Stefania Maffei, Federico Sacchetti, Laura Vandelli, Maria Luisa Dell'Acqua, Livio Picchetto, Giuseppe Maria Borz ì, Riccardo Ricceri, Roberta Pentore, Manuela Tondelli, Gabriele Vandelli, Noelia Rodrà Source Type: research

CYP2C19 Loss-of-Function is Associated with Increased Risk of Ischemic Stroke after Transient Ischemic Attack in Intracranial Atherosclerotic Disease
Intracranial atherosclerotic disease (ICAD) is responsible for 8-10% of acute ischemic strokes, and resistance to antiplatelet therapy is prevalent. CYP2C19 gene loss-of-function (up to 45% of patients) causes clopidogrel resistance. For patients with asymptomatic ICAD and ICAD characterized by transient ischemic attack (TIA), this study measures the effect of CYP2C19 loss-of-function on ischemic stroke risk during clopidogrel therapy.
Source: Journal of Stroke and Cerebrovascular Diseases - November 24, 2020 Category: Neurology Authors: Pious D. Patel, Praveen Vimalathas, Xinnan Niu, Chevis N. Shannon, Joshua C. Denny, Josh F. Peterson, Rohan V. Chitale, Matthew R. Fusco Source Type: research

Predictors of Clopidogrel Hyper-Responsiveness in Neuro-Interventional Procedures
Hyper-responsiveness to clopidogrel abnormally inhibits platelet aggregation and increases hemorrhagic complications. The present study investigated clinical factors related to clopidogrel hyper-responsiveness in neuro-interventional procedures.
Source: Journal of Stroke and Cerebrovascular Diseases - November 5, 2020 Category: Neurology Authors: Ryotaro Suzuki, Masaya Nagaishi, Issei Takano, Tomoji Takigawa, Akio Hyodo, Kensuke Suzuki Source Type: research

Ipsilateral Nonstenotic Carotid Disease in Minor Ischemic Stroke: an Exploratory Analysis of The POINT Randomized Clinical Trial
Dual antiplatelet therapy, with combination aspirin and clopidogrel, is now standard of care in the secondary prevention of minor stroke and transient ischemic attack1 –3 as well as stroke due to intracranial atherosclerotic disease.4 However, in the Clopidogrel in High-risk patients with Acute Nondisabling Cerebrovascular Events (CHANCE)2 and Platelet Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT)3 randomized clinical trials, determination of the etiology of ischemic stroke was not required to initiate secondary prevention.
Source: Journal of Stroke and Cerebrovascular Diseases - August 13, 2020 Category: Neurology Authors: Zachary Bulwa, Faddi G. Saleh Velez, James R. Brorson, Camila B. Pinto Source Type: research

High on-clopidogrel platelet reactivity in ischaemic stroke or transient ischaemic attack: Systematic review and meta-analysis
To assess the prevalence of high on-clopidogrel platelet reactivity (HCPR) in patients with ischaemic stroke or transient ischaemic attack (IS/TIA), their outcome and genetic basis of on-treatment response variability in IS/TIA patients.
Source: Journal of Stroke and Cerebrovascular Diseases - May 13, 2020 Category: Neurology Authors: Vafa Alakbarzade, Xuya Huang, Irina Chis Ster, Meriel McEntagart, Anthony C. Pereira Source Type: research

Comparison of Antiplatelet Therapies for Prevention of Patent Foramen Ovale-Associated Stroke
The REDUCE study demonstrated a reduction in the risk of recurrent stroke with patent foramen ovale closure and antiplatelet therapy compared to antiplatelet therapy alone. The clinicians were allowed to choose among aspirin, clopidogrel, or aspirin/dipyridamole with the expectation that all antiplatelet therapies would have similar efficacy in this population. We tested that presumption by comparing recurrent stroke rates among antiplatelet agents within the control arm of the trial.
Source: Journal of Stroke and Cerebrovascular Diseases - February 6, 2020 Category: Neurology Authors: Scott E. Kasner, Bryan Randall, Grethe Andersen, Helle K. Iversen, Risto Roine, Christina Sjostrand, John F. Rhodes, Lars S øndergaard, The Gore REDUCE Study Investigators Source Type: research

Platelet Surface CD62p and Serum Vitamin D Levels are Associated with Clopidogrel Resistance in Chinese Patients with Ischemic Stroke
Background: To explore the association of platelet activation markers, vitamin D, and antiplatelet drugs resistance in ischemic stroke patients. Methods: A total of 230 patients with ischemic stroke were enrolled in this study. Platelet aggregation, platelet activation marker (CD62p), and vitamin D were measured after 7-14 days of dual antiplatelet treatment (aspirin  + clopidogrel). All individuals were divided into a drug resistance group and a drug sensitive group according to the platelet maximum aggregation rate induced by antagonist adenosine diphosphate or arachidonic acid.
Source: Journal of Stroke and Cerebrovascular Diseases - February 20, 2019 Category: Neurology Authors: Bi-Chao Lu, Xiao-Jie Shi, Lin Liang, Na Dong, Zhi-Zhong Liu Source Type: research

Comparison of Effects between Clopidogrel and Cilostazol on Cerebral Perfusion in Nonsurgical Adult Patients with Symptomatically Ischemic Moyamoya Disease: Subanalysis of a Prospective Cohort
Adult patients with symptomatically ischemic moyamoya disease (MMD) initially undergo medical treatment alone including antiplatelet drugs when symptomatic cerebral hemispheres do not exhibit hemodynamic compromise. The purpose of the present study subanalyzing the same patient cohort used in a previous study was to determine which antiplatelet drug, clopidogrel or cilostazol, provides better improvement of cerebral perfusion in such patients.
Source: Journal of Stroke and Cerebrovascular Diseases - August 31, 2018 Category: Neurology Authors: Takayuki Chiba, Kengo Setta, Yasuyoshi Shimada, Jun Yoshida, Kentaro Fujimoto, Shouta Tsutsui, Kenji Yoshida, Masakazu Kobayashi, Yoshitaka Kubo, Shunrou Fujiwara, Kazunori Terasaki, Kuniaki Ogasawara Source Type: research

Secondary Stroke Prophylaxis with Clopidogrel Produces Sufficient Antiplatelet Response
Antiplatelet therapy is a cornerstone prevention strategy for secondary ischemic stroke (IS) and transient ischemic attack (TIA). Yet, a proportion of patients who receive antiplatelet therapy experience recurrent ischemic cerebrovascular events. A recent meta-analysis found an increased risk of recurrent stroke in clopidogrel- or aspirin-treated patients with ischemic stroke who had high on-treatment platelet reactivity (HTPR). Few studies have focused specifically on clopidogrel HTPR. Therefore, the aim of this study was to examine the relationship between clopidogrel HTPR and recurrent ischemic events in a population of...
Source: Journal of Stroke and Cerebrovascular Diseases - June 23, 2018 Category: Neurology Authors: Charlotte L ützhøft Rath, Niklas Rye Jørgensen, Troels Wienecke Source Type: research

Evaluating the Effect of Six Proton Pump Inhibitors on the Antiplatelet Effects of Clopidogrel
The objective of the present study was to examine the robustness of this interaction using a well-controlled study design in a population of participants free of confounders.
Source: Journal of Stroke and Cerebrovascular Diseases - February 12, 2018 Category: Neurology Authors: Eugene R. Przespolewski, Erica S. Westphal, Michelle Rainka, Nicholas M. Smith, Vernice Bates, Fran M. Gengo Source Type: research